Article

A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds

2020-06-05

Abstract excerpt

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the most pressing medical and socioeconomic challenge. Constituting important correlates of protection, determination of virus-neutralizing antibodies (NAbs) is indispensable for convalescent plasma selection, vaccine candidate evaluation, and immunity certificates. In contrast to standar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 95ab4523-fdea-5a61-9e67-2e8107819c20
DOI: 10.1101/2020.06.05.135806

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compoundsDOI 10.1101/2020.06.05.135806Read

Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2Semantic proximity Read

Development of a SARS-CoV-2 monoclonal antibody panel and its applicability as a reagent in high-throughput fluorescence reduction neutralization and immunohistochemistry assaysSemantic proximity Read

Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic testSemantic proximity Read

Rapid <i>in vitro</i> assays for screening neutralizing antibodies and antivirals against SARS-CoV-2Semantic proximity Read

Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particlesSemantic proximity Read

Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical SamplesSemantic proximity Read

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19Semantic proximity Read

IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody TitersSemantic proximity Read

A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2 Growth in Cell CultureSemantic proximity Read

Evaluation of a novel fully automated and ELISA- based assays for detecting anti- SARS- CoV-2 neutralizing antibodiesSemantic proximity Read

Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2Semantic proximity Read

A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity EvaluationSemantic proximity Read